For the quarter ended December 2024, Astrazeneca (AZN) reported revenue of $14.89 billion, up 23.8% over the same period last year. EPS came in at $1.05, compared to $0.73 in the year-ago quarter.The reported revenue represents a surprise of +4.26% over the Zacks Consensus Estimate of $14.28 billion. With the consensus EPS estimate being $1.07, the EPS surprise was -1.87%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=127264&from=4 CLASS PERIOD: February 23, 2022 to ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether AstraZeneca and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On November 5, 2024, t ...

Johnson & Johnson (JNJ) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion for the expanded use of the subcutaneous (SC) formulation of Rybrevant (amivantamab) in advanced EGFR-mutated non-small cell lung cancer (NSCLC).The CHMP recommendation is for SC Rybrevant in combination with Lazcluze (lazertinib) for the first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion (ex19del) or L858R mutation. The C ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as "a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascul ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=126295&from=3 CLASS PERIOD: February 23, ...

In its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $1.07 per share, reflecting an increase of 46.6% compared to the same period last year. Revenues are forecasted to be $14.28 billion, representing a year-over-year increase of 18.8%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a compan ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AstraZenecaTo Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 2, 2025 /PRNewswire/ ...

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit ...